

vimian™

Q3 2026

Interim report
January - September



Interim report January - September 2026

Continued strong performance

Third quarter

- Revenue increased by 15 per cent to EUR 120.3m (104.3) with organic growth of 11 per cent. Acquisitions contributed with 3 per cent and positive impact from currency movements of 1 per cent
- Operating profit (EBIT) of EUR 20.5m (17.5)
- EBITA of EUR 27.1m (23.9), including items affecting comparability of EUR -2.1m (-1.7). Adjusted EBITA increased 14 per cent to EUR 29.2m (25.5) corresponding to a margin of 24.3 per cent (24.5)
- Profit for the period of EUR 9.3m (6.8) and earnings per share before and after dilution EUR 0.02 (0.01)
- Cash flow from operating activities of EUR 22.6m (10.8)

First nine months

- Revenue increased by 13 per cent to EUR 357.9m (316.1) with organic growth of 10 per cent. Acquisitions contributed with 4 per cent and negative impact from currency movements of -2 per cent.
- Operating profit (EBIT) of EUR 64.0m (47.6)
- EBITA of EUR 83.3m (65.2), including items affecting comparability of EUR -4.8m (-14.0). Adjusted EBITA increased 11 per cent to EUR 88.1m (79.2) corresponding to a margin of 24.6 per cent (25.1)
- Profit for the period of EUR 28.1m (20.1) and earnings per share before and after dilution EUR 0.05 (0.04)
- Cash flow from operating activities of EUR 49.4m (50.1)

Significant events during the third quarter

- On 17 July, the Board resolved to carry out a new issue and subsequently repurchase a total of 2,673,064 shares, of which 1,721,174 class D shares, 475,945 class E1 2026 shares and 475,945 class E2 2026 shares as part of the implementation of LTI2026.
- On 27 August, Vimian appointed Hans Lord Skarplöth as Head of Specialty Pharma and member of the Vimian Group Management Team, effective 1 October.
- The number of votes in Vimian changed during August as a result of the conversion of a total of 166,405 C shares into an equal number of ordinary shares and the number of votes has increased by 149,764.5.
- On 14 September, Martin Bengtson, Head of M&A and member of the Vimian Group management team, decided to step down and Andrea Tidholm was appointed new Head of M&A reporting into CFO Carl-Johan Zetterberg Boudrie, effective 5 October.

Significant events after the third quarter

- No significant events occurred after the end of the third quarter.

Financial key ratios

EURm, unless otherwise stated	Jul-Sep 2026	Jul-Sep 2025	Δ%	Jan-Sep 2026	Jan-Sep 2025	Δ%	Oct-Sep 25/26	Full-year 2025
Revenue	120.3	104.3	15%	357.9	316.1	13%	466.9	425.0
Organic revenue growth (%) ¹	11%	9%		10%	6%			6%
EBITA	27.1	23.9	14%	83.3	65.2	28%	108.8	90.7
EBITA margin (%)	22.5%	22.9%	-0.4 pp	23.3%	20.6%	2.7 pp	23.3%	21.3%
Adjusted EBITA ¹	29.2	25.5	14%	88.1	79.2	11%	114.3	105.3
Adjusted EBITA margin (%) ¹	24.3%	24.5%	-0.2 pp	24.6%	25.1%	-0.4 pp	24.5%	24.8%
Operating profit (EBIT)	20.5	17.5	17%	64.0	47.6	34%	83.3	66.8
Profit for the period	9.3	6.8	36%	28.1	20.1	40%	40.3	32.3
Items affecting comparability ²	-2.1	-1.7		-4.8	-14.0		-5.5	-14.7
Earnings per share before dilution (EUR)	0.02	0.01		0.05	0.04		0.07	0.06
Earnings per share after dilution (EUR)	0.02	0.01		0.05	0.04		0.07	0.06
Cash flow from operating activities	22.6	10.8	110%	49.4	50.1	-1%	105.1	105.7

¹ Refer to the section on Alternative performance measures for more information.

² Refer to Note 3 and the section on Items affecting comparability for more information.

Message from our CEO

Continued strong performance

Vimian delivered another quarter with double-digit organic revenue growth and strong earnings growth. Total revenues grew 15 per cent to EUR 120.3 million with organic growth of 11 per cent. Our business continues to outperform the overall animal health market, reflecting the strength of our strategy with focus on attractive market niches, a strong brand portfolio and disciplined execution of our teams in an entrepreneurial organisation.

Adjusted EBITA grew 14 per cent to EUR 29.2 million with strong growth across all four segments. The adjusted EBITA margin reached 24.3 per cent (24.5).

Cash flow from operating activities improved compared to the second quarter and reached EUR 22.6 million.

After the end of the quarter, we signed the acquisition of Norfolk Medical Products to our MedTech segment, adding USD 6.9 million in annual revenues. The acquisition expands our offering into specialised soft tissue surgery, a high growth niche within veterinary surgery.

Specialty Pharma – underlying momentum remains strong

Specialty Pharma delivered 7 per cent organic growth driven by the therapeutic areas Allergy, Dermatology and Specialty Pharmaceuticals. As previously communicated, Specialised Nutrition was negatively impacted by a strong prior year comparison which included a national sales campaign in US that we completed in the second quarter of this year.

During the quarter we launched an updated version of our allergy test platform Pet Allergy Explorer (PAX), that covers an additional 25 allergens. PAX is the world's most advanced veterinary allergy test, and several scientific studies reaffirm the test platform's ability to outperform other blood-based allergy tests on the market.

The adjusted EBITA margin improved to 30.3 per cent (29.5).

MedTech – continued double-digit growth

MedTech achieved 15 per cent organic growth, with the dental business continuing to deliver strong growth, driven by disciplined commercial execution and deepened penetration of key customer accounts in the US in a market niche with unmet medical needs. We also see continued positive momentum in our orthopedics business, including the previously underperforming North American market, where we delivered another quarter of growth. We educated 1,300 veterinarians in the quarter to unlock long-term market growth in both orthopedics and dentistry.

The adjusted EBITA margin improved to 24.4 per cent (23.7), driven by the dental business.

Veterinary Services – momentum remains

Veterinary Services delivered 10 per cent organic growth in the quarter, and we entered the new markets Portugal and Japan, with positive feedback on our service offering from the veterinary community. The adjusted EBITA margin improved to 30.5 per cent (29.1), including positive effects in the quarter from mix and our strategic partner agreements.

Diagnostics – focus on companion animal

Diagnostics delivered 13 per cent organic growth in the quarter driven by extraction and PCR test sales in the livestock business. The adjusted EBITA margin was 7.2 per cent (4.9), including our investments to diversify into companion animal diagnostics.

Clear progress across strategic initiatives

Our business is performing well, and we are making clear progress across our strategic initiatives. The M&A pipeline remains active, including both possible platform as well as bolt-on acquisitions.

During the quarter, we announced the recruitment of Hans Lord Skarplöth as Head of Specialty Pharma, and the promotion of Andrea Tidholm as Head of M&A. Our bi-annual employee survey, conducted in September, showed continued high employee engagement scores. In September, we also held our global Vimian leadership conference, further strengthening our cross-company culture and collaboration across the Group.

Looking ahead, we are well positioned to continue delivering sustainable, volume-led growth, supported by our diversified portfolio and multiple revenue streams. Our strong reputation as a preferred home for successful animal health entrepreneurs further strengthens our ability to build a global leader in attractive animal health niches through a combination of organic growth and disciplined acquisitions. On 24 November, we will host a Capital Markets Day in Stockholm to provide further insights into our strategy and the roadmap towards the 2030 financial target.



Alireza Tajbakhsh
CEO of Vimian Group AB (publ)

Group performance

Third quarter 2026

Revenue

Revenue increased by 15 per cent to EUR 120.3m (104.3). Organic revenue growth was 11 per cent driven by Specialty Pharma and MedTech with 7 per cent and 15 per cent organic growth respectively. Veterinary Services organic growth was 10 per cent. Diagnostics delivered organic growth of 13 per cent.

Acquisitions contributed with 3 per cent and positive impact of 1 per cent from currency movements.

Operating profit

Operating profit (EBIT) amounted to EUR 20.5m (17.5) at a margin of 17.0 per cent (16.8). This includes items affecting comparability of EUR -2.1m (-1.7).

Main items affecting comparability relates to acquisition costs in MedTech and Veterinary Services of EUR 1.4m and reorganisation cost in Specialty Pharma EUR 0.3m. For further information on items affecting comparability, refer to Note 3.

EBITA

EBITA increased by 14 per cent to EUR 27.1m (23.9) at a margin of 22.5 per cent (22.9).

Adjusted EBITA

Adjusted EBITA increased by 14 per cent to EUR 29.2m (25.5) at a margin of 24.3 per cent (24.5).

Financial items

Net financial items amounted to EUR -6.9m (-4.1). This consists of three main parts: (1) financing expenses of EUR -4.2m with an average interest rate of 4.0 per cent during the quarter, partly offset by interest income of EUR 0.8m; (2) a quarterly discounting impact of EUR -0.9m and negative impact of EUR -2.2m from

probability adjustments related to contingent considerations; (3) a negative impact of EUR -0.5m from exchange rate effects on the revaluation of debt.

Tax

Income tax expense for the quarter was EUR -4.3m (-6.6) at an effective tax rate of 31 per cent. In the quarter the tax expense as percentage of pre-tax profit was negatively affected by probability adjustments related to contingent considerations and other non-deductible expenses.

Profit for the period

Profit for the period amounted to EUR 9.3m (6.8), negatively impacted by EUR -0.5m from exchange rates included in financial items and by EUR -2.2m from probability adjustment on contingent liabilities. Earnings per share before and after dilution amounted to EUR 0.02 (0.01).


Cash flow

Cash flow from operating activities amounted to EUR 22.6m (10.8). Cash flow from investing activities of EUR -21.0m (-5.1) primarily consisting of acquisitions and earn-out payments. Cash flow from financing activities amounts to EUR 2.4m (-22.0).


Net working capital

Net working capital amounted to EUR 116.4m (102.2) per the end of September at 25 (25) per cent of revenue, an increase from EUR 114.1m at the end of June 2026 (26 per cent of revenue). The increase in net working capital compared to last year is mainly driven by higher inventories in MedTech to manage strong demand in the dental business. Compared to end of June 2026, net working capital increased by EUR 2.3m.

Quarterly revenue



Quarterly adjusted EBITA



Capital expenditure

Capital expenditure amounted to EUR -4.1m (-3.1). This is split between EUR -2.9m investments in intangible assets (internal R&D, software development and R&D partnerships) and EUR -1.2m investments in property, plant and equipment.

The capex of EUR -4.1m accounts for 3.4 per cent of sales, compared to 2.9 per cent for the same period in the previous year. The higher capex as a percentage of sales is due to higher investments in capitalized R&D as well as investments in premises.

Net debt and cash and cash equivalents

At the end of the period, net debt amounted to EUR 262.4m (253.5), a decrease from EUR 273.7m per 30 June 2026. Cash

and cash equivalents amounted to EUR 55.6m (51.3) an increase compared to EUR 51.6m at the end of June. External lending amounted to EUR 263.1m (254.0).

Per 30 September, net debt in relation to pro-forma adjusted EBITDA over the past 12-month period was 2.0x, a decrease from 2.1x per 30 June 2026.

Central Costs

Central costs amounted to EUR -3.0m (-1.8). Central costs include EUR -0.6m expenses related to the 2024, 2025 and 2026 long term incentive programmes (employee stock options and investment shares). These are non-cash IFRS expenses that will recur for the duration of the three-year programs.

January to September 2026

Revenue

Revenue increased by 13 per cent to EUR 357.9m (316.1). Organic revenue growth was 10 per cent driven by Specialty Pharma and MedTech with 11 per cent organic growth respectively. Veterinary Services organic growth was 10 per cent. Diagnostics delivered organic growth of 11 per cent.

Acquisitions contributed with 4 per cent and negative impact of -2 per cent from currency movements.

Operating profit

Operating profit (EBIT) amounted to EUR 64.0m (47.6) at a margin of 17.9 per cent (15.1). This includes items affecting comparability of EUR -4.8m (-14.0).

Most items affecting comparability relates to acquisition costs in MedTech, Veterinary Services and Diagnostics of EUR -3.2m. In MedTech, the litigation costs in the US indemnification dispute amounted to EUR -1.1m. For further information on items affecting comparability, refer to Note 3.

EBITA

EBITA increased by 28 per cent to EUR 83.3m (65.2) at a margin of 23.3 per cent (20.6).

Adjusted EBITA

Adjusted EBITA increased by 11 per cent to EUR 88.1m (79.2) at a margin of 24.6 per cent (25.1).

Financial items

Net financial items amounted to EUR -18.2m (-13.1). This consists of three main parts: (1) financing expenses of EUR -10.5m, with an average interest rate of 4.0 per cent during the period, partly offset by interest income of EUR 1.2m; (2) a discounting impact of EUR -3.2m and negative impact of EUR -4.5m from probability adjustments related to contingent considerations; (3) a negative impact of EUR -1.2m from exchange rate effects on the revaluation of debt.

Tax

Income tax expense for the period was EUR -15.1m (-14.3) at an effective tax rate of 35 per cent. The tax expense as percentage of pre-tax profit was negatively affected by probability adjustments related to contingent considerations and other non-deductible expenses.

Profit for the period

Profit for the period amounted to EUR 28.1m (20.1), negatively impacted by EUR -1.2m from exchange rates included in financial items and by EUR -4.5m from probability adjustment on contingent liabilities. Earnings per share before and after dilution amounted to EUR 0.05 (0.04).

Cash flow

Cash flow from operating activities amounted to EUR 49.4m (50.1). Cash flow from investing activities of EUR -77.5m (-95.3) primarily consisting of acquisitions and earn-out payments. Cash flow from financing activities amounts to EUR 28.0m (34.2).

Capital expenditure

Capital expenditure amounted to EUR -15.6m (-9.3). This is split between EUR -7.7m investments in intangible assets (internal R&D, software development and R&D partnerships) and EUR -7.9m investments in property, plant and equipment (the larger investments include leasehold improvements and expansion of premises in MedTech and Specialty Pharma).

Central Costs

Central costs amounted to EUR -8.9m (-6.2). Central costs include EUR -1.8m expenses related to the 2024, 2025 and 2026 long term incentive programmes (employee stock options and investment shares). These are non-cash IFRS expenses that will recur for the duration of the three-year programs.

Segment performance

Third quarter 2026

Vimian operates through four reporting segments: Specialty Pharma, MedTech, Veterinary Services and Diagnostics


Revenue

	Jul-Sep 2026	Jul-Sep 2025	Δ	Jan-Sep 2026	Jan-Sep 2025	Δ	Oct-Sep 25/26	Full-year 2025
Specialty Pharma	50.3	46.2	9%	149.0	136.4	9%	195.0	182.4
MedTech	43.2	37.1	16%	130.4	115.4	13%	170.6	155.5
Veterinary Services	19.3	15.8	22%	56.2	47.5	18%	73.0	64.3
Diagnostics	7.4	5.2	44%	22.2	16.8	32%	28.3	22.9
Group	120.3	104.3	15%	357.9	316.1	13%	466.9	425.0


Adjusted EBITA

	Jul-Sep 2026	Jul-Sep 2025	Δ	Jan-Sep 2026	Jan-Sep 2025	Δ	Oct-Sep 25/26	Full-year 2025
Specialty Pharma	15.2	13.6	12%	45.0	40.1	12%	58.8	53.9
MedTech	10.5	8.8	20%	33.6	29.7	13%	43.5	39.6
Veterinary Services	5.9	4.6	28%	16.2	13.9	16%	20.7	18.4
Diagnostics	0.5	0.3	111%	2.2	1.6	36%	2.8	2.2
Group Functions	-3.0	-1.8	70%	-8.9	-6.2	44%	-11.5	-8.8
Group	29.2	25.5	14%	88.1	79.2	11%	114.3	105.3

Revenue per segment, Q3 2026



Adjusted EBITA per segment, Q3 2026¹



¹ Adjusted EBITA before central costs.

Segment – Specialty Pharma

EURm	Jul-Sep 2026	Jul-Sep 2025	Δ	Jan-Sep 2026	Jan-Sep 2025	Δ	Oct-Sep 25/26	Full-year 2025
Revenue	50.3	46.2	9%	149.0	136.4	9%	195.0	182.4
Organic revenue growth (%)	7%	11%	-4 pp	11%	9%	2 pp		8%
EBITA	14.8	13.6	9%	44.3	39.6	12%	58.0	53.3
EBITA margin (%)	29.5%	29.5%	-0.0 pp	29.8%	29.1%	0.7 pp	29.8%	29.2%
Adjusted EBITA	15.2	13.6	12%	45.0	40.1	12%	58.8	53.9
Adjusted EBITA margin (%)	30.3%	29.5%	0.8 pp	30.2%	29.4%	0.8 pp	30.2%	29.6%

Revenue

Revenue in the third quarter grew 9 per cent to EUR 50.3 million (46.2). Organic growth was 7 per cent, with no contribution from acquisitions and 2 per cent positive impact from currency movements.

Growth was driven by double-digit organic growth in three out of four therapeutic areas. The therapeutic area Specialised Nutrition was negatively impacted by a strong prior year comparison which included a national sales campaign in US that was completed in the second quarter of this year. Adjusting for the impact from these campaigns, organic growth in Specialty Pharma was 11 per cent in the third quarter.

12 new products were launched during the third quarter.


Net revenue during January to September grew 9 per cent to EUR 149.0 million (136.4). Organic growth of 11 per cent, with no contribution from acquisitions and -1 per cent negative impact from currency movements.

Adjusted EBITA


Adjusted EBITA in the third quarter increased by 12 per cent to EUR 15.2 million (13.6) at a margin of 30.3 per cent (29.5). The year-over-year margin improvement was driven by revenue growth and an improved gross margin.

Adjusted EBITA for the period January to September increased by 12 per cent to EUR 45.0 million (40.1) at a margin of 30.2 per cent (29.4).

Quarterly revenue Specialty Pharma



Quarterly adjusted EBITA Specialty Pharma



Segment – MedTech

EURm	Jul-Sep 2026	Jul-Sep 2025	Δ	Jan-Sep 2026	Jan-Sep 2025	Δ	Oct-Sep 25/26	Full-year 2025
Revenue	43.2	37.1	16%	130.4	115.4	13%	170.6	155.5
Organic revenue growth (%)	15%	5%	9 pp	11%	- 3%	13 pp		- 1%
EBITA	9.4	7.8	21%	30.9	19.5	58%	41.3	29.9
EBITA margin (%)	21.7%	20.9%	0.8 pp	23.7%	16.9%	6.8 pp	24.2%	19.2%
Adjusted EBITA	10.5	8.8	20%	33.6	29.7	13%	43.5	39.6
Adjusted EBITA margin (%)	24.4%	23.7%	0.6 pp	25.8%	25.8%	0.0 pp	25.5%	25.5%

Revenue

Revenue in the third quarter increased 16 per cent to EUR 43.2 million (37.1). Organic growth of 15 per cent, with no contribution from acquisitions and 2 per cent positive impact from currency movements.

Organic growth was driven by continued double-digit growth in both the dental and the orthopedics business. In the dental business, North America and Asia-Pacific delivered strong growth, and in orthopedics growth was mainly driven by Europe and Asia-Pacific. The orthopedics business in North America delivered low single-digit organic growth in the quarter.


Net revenue during January to September grew 13 per cent to EUR 130.4 million (115.4). Organic growth of 11 per cent, with 5 per cent contribution from acquisitions in veterinary dental and -2 per cent negative impact from currency movements.

Adjusted EBITA


Adjusted EBITA in the third quarter increased by 20 per cent to EUR 10.5 million (8.8) at a margin of 24.4 per cent (23.7). The margin improvement was driven by strong growth and improved gross margin in the dental business.

Adjusted EBITA for the period January to September increased by 13 per cent to EUR 33.6 million (29.7) at a margin of 25.8 per cent (25.8).

Quarterly revenue MedTech



Quarterly adjusted EBITA MedTech



Segment – Veterinary Services

EURm	Jul-Sep 2026	Jul-Sep 2025	Δ	Jan-Sep 2026	Jan-Sep 2025	Δ	Oct-Sep 25/26	Full-year 2025
Revenue	19.3	15.8	22%	56.2	47.5	18%	73.0	64.3
Organic revenue growth (%)	10%	11%	-2 pp	10%	12%	-2 pp		11%
EBITA	5.5	4.6	20%	14.1	13.8	2%	18.3	18.0
EBITA margin (%)	28.5%	29.1%	-0.7 pp	25.1%	29.0%	-4.0 pp	25.1%	28.1%
Adjusted EBITA	5.9	4.6	28%	16.2	13.9	16%	20.7	18.4
Adjusted EBITA margin (%)	30.5%	29.1%	1.4 pp	28.8%	29.3%	-0.6 pp	28.3%	28.6%

Revenue

Revenue for the third quarter grew 22 per cent to EUR 19.3 million (15.8). Organic growth of 10 per cent, with 13 per cent contribution from acquisitions and no impact from currency movements.

The member base continued to increase reaching 12,400 members by the end of the third quarter. The combination of continued growth in new members, an increased share of wallet and strategic partnerships supported the organic growth, with strong development in the US.

Co-owned clinics accounted for approximately a third of segment revenue and delivered low single-digit growth in the quarter.

Net revenue during January to September grew 18 per cent to EUR 56.2 million (47.5). Organic growth of 10 per cent, with 9 per cent contribution from acquisitions and -1 per cent negative impact from currency movements.


Adjusted EBITA

Adjusted EBITA for the third quarter increased 28 per cent to EUR 5.9 million (4.6) at a margin of 30.5 per cent (29.1).


The year-over-year margin improvement was mainly driven by mix towards higher-margin services as well as positive effects in the quarter from our strategic partner agreements.

Adjusted EBITA for the period January to September increased by 16 per cent to EUR 16.2 million (13.9) at a margin of 28.8 per cent (29.3)

Quarterly revenue Veterinary Services



Quarterly adjusted EBITA Veterinary Services



Segment – Diagnostics

EURm	Jul-Sep 2026	Jul-Sep 2025	Δ	Jan-Sep 2026	Jan-Sep 2025	Δ	Oct-Sep 25/26	Full-year 2025
Revenue	7.4	5.2	44%	22.2	16.8	32%	28.3	22.9
Organic revenue growth (%)	13%	4%	9 pp	11%	13%	-2 pp		10%
EBITA	0.4	0.2	153%	1.7	1.4	18%	1.7	1.4
EBITA margin (%)	5.3%	3.0%	2.3 pp	7.6%	8.5%	-0.9 pp	6.0%	6.3%
Adjusted EBITA	0.5	0.3	111%	2.2	1.6	36%	2.8	2.2
Adjusted EBITA margin (%)	7.2%	4.9%	2.3 pp	9.9%	9.7%	0.2 pp	9.8%	9.5%

Revenue

Revenue in the third quarter increased by 44 per cent to EUR 7.4 million (5.2). Organic growth of 13 per cent, with 30 per cent contribution from acquisitions and 1 per cent positive impact from currency movements.

Organic growth was mainly driven by sales of extraction and PCR products in the livestock business. The companion animal diagnostics business, including I-Vet, continued to deliver strong growth.

Net revenue during January to September grew 32 per cent to EUR 22.2 million (16.8). Organic growth of 11 per cent, with 22 per cent contribution from acquisitions and no impact from currency movements.


Adjusted EBITA

Adjusted EBITA for the third quarter amounted to EUR 0.5 million (0.3) at a margin of 7.2 per cent (4.9).

The margin improvement was driven by revenue growth, partly offset by continued investments in the companion animal diagnostics business.

Adjusted EBITA for the period January to September increased by 36 per cent to EUR 2.2 million (1.6) at a margin of 9.9 per cent (9.7).

Quarterly revenue Diagnostics



Quarterly adjusted EBITA Diagnostics



Declaration of the Board of Directors and Chief Executive Officer

The Board of Directors and Chief Executive Officer declare that the interim report provides a true and fair view of the development of the Group's and parent company's business, its financial position and results, and describes significant risks and uncertainties faced by the parent company and the companies included in the Group.

Stockholm, 22 October 2026

Magnus Welander
Chairman

Gabriel Fitzgerald

Pia Marions

Petra Rumpf

Theodor Bonnier

Alireza Tajbakhsh
Group CEO

This report has been reviewed by the company's auditors.

Prior to publication this information constituted inside information that Vimian Group AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the above contact persons, at 07:45 am CEST on 22 October 2026.

Webcast conference call on 22 October 2026: In connection with the interim report, Vimian will hold a webcast conference call in English at 09:00 am CEST. Vimian will be represented by CEO Alireza Tajbakhsh and CFO Carl-Johan Zetterberg Boudrie, who will present the interim report and answer questions. Information regarding telephone numbers is available at www.vimian.com/investors. The presentation will be available at www.vimian.com/investors after publication of the interim report. The webcast will be available at the same address after the live broadcast.

Report on Review of Interim Financial Information

Introduction

We have reviewed the interim financial information (interim report) for Vimian Group AB per 30 September 2026 and for the nine-month period then ended. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on

Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not, in all material respects, prepared for the Group in accordance with IAS 34 and the Annual Accounts Act, and for the Parent Company in accordance with the Annual Accounts Act.

Stockholm 22 October 2026

Grant Thornton Sweden AB

Camilla Nilsson

Authorized Public Accountant

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS

EURm unless otherwise stated	Note	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Full-year 2025
Revenue from contracts with customers	3, 4	120.3	104.3	357.9	316.1	425.0
Revenue		120.3	104.3	357.9	316.1	425.0
Other operating income	10	1.1	0.6	3.6	2.3	3.3
Raw material and merchandise		-36.8	-32.0	-110.1	-96.9	-132.2
Other external expenses	10	-20.3	-18.7	-61.5	-64.4	-81.4
Personnel expenses		-32.1	-26.5	-91.7	-80.5	-108.2
Depreciation and amortisation		-11.3	-9.9	-32.0	-27.8	-37.9
Other operating expenses		-0.4	-0.3	-2.2	-1.2	-1.8
Operating profit		20.5	17.5	64.0	47.6	66.8
Net financial items		-6.9	-4.1	-18.1	-13.1	-20.6
Share of profit of an associate		-0.0	-	-2.5	-	-0.3
Profit before tax		13.6	13.4	43.3	34.4	45.9
Income tax expense		-4.3	-6.6	-15.1	-14.3	-13.5
Profit for the period		9.3	6.8	28.1	20.1	32.3
Profit for the period attributable to:						
Equity holders of the parent		8.9	6.5	27.1	19.2	31.3
Non-controlling interests		0.4	0.3	1.1	1.0	1.1
Earnings per share, before dilution (EUR)		0.02	0.01	0.05	0.04	0.06
Earnings per share, after dilution (EUR)		0.02	0.01	0.05	0.04	0.06
Average number of shares, before dilution (Thousands)		532,438	526,707	530,357	524,960	525,701
Average number of shares, after dilution (Thousands)		535,146	526,820	533,066	525,072	525,701
Number of shares at the end of the period (Thousands)		533,319	526,903	533,319	526,903	529,263

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

EURm	Note	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Full-year 2025
Profit for the period		9.3	6.8	28.1	20.1	32.3
Other comprehensive income						
Items that may be reclassified to profit or loss:						
Exchange differences on translation of foreign operations		9.2	-3.5	17.8	-41.5	-41.5
Remeasurement of interest derivatives to fair value		-3.9	-	1.3	-	-
Items that will not be reclassified to profit or loss:						
Remeasurement of defined benefit plans		-0.0	0.0	0.1	0.1	-0.0
Other comprehensive income for the period, net of tax		5.3	-3.5	19.2	-41.4	-41.5
Total comprehensive income for the period, net of tax		14.6	3.3	47.3	-21.3	-9.2
Total comprehensive income attributable to:						
Equity holders of the parent		13.5	3.0	45.6	-20.5	-8.7
Non-controlling interests		1.0	0.3	1.7	-0.8	-0.4

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

EURm	Note	30 Sep 2026	30 Sep 2025	31 Dec 2025
Non-current assets				
Goodwill		626.5	589.0	590.1
Intangible assets		239.0	240.4	238.9
Property, plant and equipment		37.8	29.7	31.6
Right-of-use assets		16.4	15.4	14.8
Investment in associates		13.0	9.3	14.1
Non-current financial assets		2.1	24.6	1.5
Deferred tax assets		6.8	1.5	5.2
Total non-current assets		941.6	909.9	896.3
Current assets				
Inventories		98.3	80.9	80.1
Trade receivables		67.5	57.6	57.3
Current tax receivables		4.5	2.2	1.2
Other receivables		6.9	8.5	6.7
Prepaid expenses and accrued income		14.6	12.2	13.2
Cash and cash equivalents		55.6	51.3	55.0
Total current assets		247.4	212.6	213.5
TOTAL ASSETS		1,189.0	1,122.5	1,109.8

EURm	Note	30 Sep 2026	30 Sep 2025	31 Dec 2025
Equity				
Share capital		0.1	0.1	0.1
Other contributed capital		629.7	625.1	626.4
Reserves		-19.4	-36.2	-36.5
Retained earnings including this period's profit		137.5	97.0	109.0
Total equity attributable to equity holders of the parent		747.9	686.1	699.0
Non-controlling interests		11.0	9.6	9.9
Total equity		758.9	695.7	708.9
Non-current liabilities				
Bonds		150.0	150.0	150.0
Liabilities to credit institutions		113.1	104.0	73.3
Lease liabilities		12.1	11.0	10.3
Deferred tax liabilities		34.7	36.9	35.5
Other non-current liabilities		28.2	28.8	20.9
Non-current provisions		1.3	1.5	1.6
Total non-current liabilities		339.5	332.2	291.6
Current liabilities				
Lease liabilities		5.0	5.0	5.1
Trade payables		28.1	18.5	20.1
Current tax liabilities		10.3	10.6	10.3
Other current liabilities		21.4	38.8	53.9
Accrued expenses and prepaid income		24.1	21.4	19.2
Provisions		1.6	0.3	0.8
Total current liabilities		90.6	94.6	109.4
TOTAL EQUITY AND LIABILITIES		1,189.0	1,122.5	1,109.8

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

EURm	Equity attributable to equity holders of the parent					Non-controlling interests	Total equity
	Share capital	Other contributed capital	Translation reserve	Retained earnings including this period's profit	Total equity attributable to equity holders of the parent		
Opening balance 1 January 2025	0.1	614.9	3.5	81.5	699.9	6.6	706.5
Profit for the period				19.2	19.2	1.0	20.1
Other comprehensive income			-39.6		-39.6	-1.7	-41.4
Total comprehensive income	-	-	-39.6	19.2	-20.4	-0.8	-21.2
Transactions with owners							
Share issue		10.1			10.1		10.1
Transaction costs		-0.1			-0.1		-0.1
Warrant programme		0.4			0.4		0.4
Transactions with non-controlling interests				-3.7	-3.7	3.7	-
Total	-	10.3	-	-3.7	6.6	3.7	10.3
Closing balance 30 September 2025	0.1	625.1	-36.2	97.0	686.1	9.6	695.7
Opening balance 1 January 2026	0.1	626.4	-36.5	109.0	699.0	9.9	708.9
Profit for the period				27.1	27.1	1.1	28.1
Other comprehensive income			17.1	1.4	18.6	0.6	19.2
Total comprehensive income	-	-	17.1	28.5	45.6	1.7	47.3
Transactions with owners							
Share issue	0.0	3.5			3.5		3.5
Transaction costs		-0.1			-0.1		-0.1
Warrant program		-0.0			-0.0		-0.0
Transactions with non-controlling interests				-0.1	-0.1	-0.6	-0.6
Total	0.0	3.4	-	-0.1	3.3	-0.6	2.8
Closing balance 30 September 2026	0.1	629.7	-19.4	137.5	747.9	11.0	758.9

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

EURm	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Full-year 2025
Operating activities					
Operating profit	20.5	17.5	64.0	47.6	66.8
Adjustments for non-cash items	10.9	8.8	33.0	40.4	54.4
Interest received	0.5	0.4	1.2	1.4	1.2
Interest paid	-3.3	-4.0	-9.8	-10.0	-15.7
Paid income tax	-6.3	-9.0	-23.7	-13.3	-17.4
Cash flow from operating activities before change in working capital	22.2	13.7	64.7	66.1	89.3
Change in inventories	-4.7	-1.1	-16.5	-7.6	-6.7
Change in operating receivables	4.4	3.3	-11.3	-6.1	20.9
Change in operating liabilities	0.6	-5.1	12.4	-2.3	2.3
Cash flow from operating activities	22.6	10.8	49.4	50.1	105.7
Investing activities					
Acquisition of a subsidiary, net of cash acquired, Note 5 and 6	-16.3	-1.3	-62.6	-87.2	-92.2
Investments in associates	-0.4	-0.0	-0.4	-0.0	-5.1
Proceeds from sale of associates	-	-	-	-	0.1
Investments in intangible assets	-2.9	-1.2	-7.7	-3.6	-6.0
Proceeds from sale of intangible assets	0.3	-	1.4	-	-
Investments in property, plant and equipment	-1.2	-1.9	-7.9	-5.7	-9.1
Proceeds from sale of property, plant and equipment	-0.0	0.0	-0.0	0.0	0.1
Investments in financial assets	-0.4	-0.7	-0.3	1.3	-0.5
Cash flow from investing activities	-21.0	-5.1	-77.5	-95.3	-112.8
Financing activities					
New share issue	-0.0	-	3.4	10.1	10.5
Warrant program	0.0	0.2	-	0.4	-0.0
Share issue - Transaction costs	-	-0.1	-	-0.1	-0.1
Proceeds from borrowings	17.9	-0.4	60.3	272.4	277.8
Repayment of borrowings	-13.6	-20.5	-31.0	-245.0	-284.1
Payment of lease liabilities	-1.5	-1.2	-4.3	-3.6	-4.9
Transactions with non-controlling interests	-0.4	-	-0.4	-	-0.4
Cash flow from financing activities	2.4	-22.0	28.0	34.2	-1.2
Cash flow for the period	4.0	-16.3	-0.1	-11.0	-8.3
Cash and cash equivalents at beginning of the period	51.6	67.5	55.0	64.8	64.8
Exchange-rate difference in cash and cash equivalents	0.0	-	0.6	-2.6	-1.5
Cash and cash equivalents at end of the period	55.6	51.3	55.6	51.3	55.0

CONDENSED PARENT COMPANY INCOME STATEMENT AND BALANCE SHEET

SEKm	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Full-year 2025
Revenue	18.9	11.1	64.4	35.5	61.0
Other operating income	0.0	0.0	0.0	0.0	0.0
Total operating income	18.9	11.1	64.4	35.5	61.0
Other external expenses	-11.8	-13.2	-34.1	-38.7	-48.9
Personnel expenses	-26.5	-13.6	-43.0	-63.3	-75.7
Depreciation and amortisation	-0.8	-0.7	-2.3	-2.2	-2.9
Other operating expenses	-0.1	-0.2	-0.3	-1.8	-2.1
Operating profit	-20.3	-16.5	-15.3	-70.5	-68.6
Group contributions	0.0	0.0	0.0	0.0	285.4
Net financial items ¹	132.6	-7.5	370.2	-177.3	-212.4
Profit before tax	112.2	-24.0	354.9	-247.9	4.5
Income tax expense	0.0	-16.1	0.0	-16.1	24.4
Profit for the period	112.2	-40.2	354.9	-264.0	28.9

¹ Net Financial items for the year includes interest income of SEK 239.0m (255.6), dividend from subsidiary 0.0 (95.0), interest expenses (including bank fees) of SEK -116.5 (-127.9) and exchange rate differences of SEK 247.5 (-400.1).

SEKm	30 Sep 2026	30 Sep 2025	31 Dec 2025
ASSETS			
Non current assets			
Own work capitalised	8.2	11.0	10.3
Other intangible assets	0.8	-	-
Property, plant and equipment	0.1	0.2	0.2
Shares in subsidiaries	6,604.7	6,242.1	6,254.3
Receivables from group companies	7,574.2	7,175.4	6,840.1
Deferred tax asset	40.6	-	40.6
Other non current assets	16.7	-	-
Total non-current assets	14,245.3	13,428.7	13,145.5
Current assets			
Receivables from group companies	287.1	220.0	399.2
Other receivables	-0.0	0.2	2.5
Prepaid expenses and accrued income	2.9	4.9	82.9
Cash and cash equivalents	-	-	-
Total current assets	290.0	225.1	484.6
TOTAL ASSETS	14,535.3	13,653.8	13,630.1
EQUITY AND LIABILITIES			
Equity			
Share capital	0.9	0.9	0.9
Development fund	8.3	13.1	10.3
Fair value fund	16.7	-	2.5
Share premium	8,420.5	8,387.9	8,381.1
Retained earnings	2,135.9	2,064.4	2,084.2
Profit for the period	354.9	-264.0	28.9
Total equity	10,937.1	10,202.3	10,507.8
Non-current liabilities			
Bonds	1,699.7	1,607.0	1,607.0
Liabilities to credit institutions	1,280.8	1,197.2	781.7
Total non-current liabilities	2,980.4	2,804.2	2,388.7
Current liabilities			
Payables to Group companies	596.7	594.3	680.7
Trade payables	3.4	2.2	6.7
Other current liabilities	2.7	1.4	23.8
Current income tax liabilities	0.8	0.4	0.4
Accrued expenses and prepaid income	14.1	49.0	22.0
Total current liabilities	617.8	647.3	733.6
TOTAL EQUITY AND LIABILITIES	14,535.3	13,653.8	13,630.1

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Significant accounting policies

The interim condensed consolidated financial statements comprise of the Swedish parent company Vimian Group AB (publ), with corporate identity number 559234-8923, and its subsidiaries. The Group's primary operations are offering products and services in animal health for domestic pets and livestock around the world. The Group offers goods and services in medicine, diagnostics and medtech as well as services and advice for veterinary professionals. The Parent Company is a limited liability company with its registered office in Stockholm, Sweden. The address of the head office is Riddargatan 19, 114 57 Stockholm.

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and interpretations issued by the IFRS Interpretations Committee (IFRS IC) as adopted by the European Union (EU) and RFR1.

The Group's interim report is prepared in accordance with IAS 34 Interim financial reporting and applicable parts of the Swedish Annual Accounts Act (1995:1554). The interim report of the parent company is prepared in accordance with the Swedish Annual Accounts Act chapter 9, Interim financial reporting and Recommendation RFR 2 Accounting for Legal Entities. The Group and Parent Company have applied the same accounting principles, basis of calculation, and assumptions as those applied in the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2025.

For a complete description of the Group's and Parent Company's applied accounting principles, see note 1 of the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2025. Disclosures according to IAS 34 are presented in the financial statements as well as corresponding notes on page 14-26, which are an integrated part of the interim condensed consolidated financial statements. All amounts are presented in millions of Euro ("MEUR"), unless otherwise indicated.

Note 2. Key estimates and assumptions

In preparing the interim financial statements, corporate management and the Board of Directors must make certain assessments and assumptions that impact the carrying amount of asset and liability items and revenue and expense items, as well as other information provided. The actual outcome may then differ from these assessments if other conditions arise. The key estimates and assumptions correspond to the ones described in the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2025.

Significant estimates during the financial year 2026 concerns the value of the non-current receivable related to the US patent litigation. On 4 April 2023, Vimian's subsidiary Veterinary Orthopedic Implants LLC ("VOI") reached a settlement agreement with DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. resolving the patent dispute between the parties. Under the terms of the agreement, Vimian paid USD 70 million during the second quarter of 2023.

In the indemnification dispute with the VOI sellers, VOI entered into settlement agreements with three of the four sellers in 2024. Each of the three sellers agreed to compensate Vimian for their entire pro rata shares of the USD 70 million settlement payment to DePuy Synthes. The total value of the three settlements amounts to approximately USD 32 million of which approximately USD 9 million has been contributed by means of dismissal of the contingent closing note from the acquisition of VOI.

On 29 August 2025, the Superior Court of Delaware awarded Vimian USD 40.2 million in damages in the indemnification dispute with the largest seller of VOI. On 1 October 2025 the court confirmed the decision from 29 August. Together with the previously reached settlements with the other sellers, this means that Vimian is entitled to compensation exceeding the USD 70 million settlement paid by Vimian to DePuy Synthes. The largest seller appealed the court decision. The Supreme Court trial took place in Q2 in Dover, Delaware and rendered its opinion on 24 September 2026. The Supreme Court largely confirmed the win in the Superior Court. The Supreme Court decision cannot be appealed.

During Q4 2025, the largest seller paid USD 31.9 million. The remaining debt from the largest seller amounts to USD 6.2 million. The payments received exceed the reported receivables on the seller by EUR 2.9 million. Vimian has not reported a provision for the on-going litigation and has also considered the remaining receivable on the seller as doubtful and therefore has not recorded any value in the financial statements. There are no changes in our assessment compared to year-end 2025.

Note 3. Operating segments

mEUR	Specialty			Veterinary	Total	Group		Group
Jul-Sep 2026	Pharma	MedTech	Diagnostics	Services	segments	functions	Eliminations	total
Revenue								
Revenue from external customers	50.3	43.2	7.4	19.3	120.3	-	-	120.3
Revenue from internal customers	0.0	0.0	0.0	0.1	0.2	-	-0.2	-
Total revenue	50.3	43.3	7.4	19.5	120.5	-	-0.2	120.3
Adjusted EBITA	15.2	10.5	0.5	5.9	32.2	-3.0	-0.0	29.2
Items affecting comparability	-0.4	-1.2	-0.1	-0.4	-2.1	-0.0	-	-2.1
EBITA	14.8	9.4	0.4	5.5	30.1	-3.0	-0.0	27.1
Amortisation of acquisition-related intangible assets	-3.1	-2.3	-0.3	-0.9	-6.6	-	-	-6.6
Net financial items	-4.7	-6.8	-1.1	-3.0	-15.7	8.7	-	-6.9
Share of profit of an associate and joint venture	-	-	-0.0	-	-0.0	-	-	-0.0
Profit before tax	7.0	0.3	-1.1	1.6	7.8	5.7	-0.0	13.6
Specification of items affecting comparability								
Acquisition-related costs	0.1	1.0	0.1	0.4	1.6	-	-	1.6
Systems update	-	-	-	-	-	-	-	-
Restructuring costs	0.3	0.0	-0.0	-0.0	0.3	-	-	0.3
IPO and financing related costs	-	-	-	-	-	-	-	-
Other	-0.0	0.1	0.0	-0.0	0.2	0.0	-	0.2
Total items affecting comparability	0.4	1.2	0.1	0.4	2.1	0.0	-	2.1
Other disclosures								
Investments	2.0	0.6	1.2	0.4	4.1	-0.0	-	4.1
Total assets	539.0	470.5	85.0	195.8	1,290.4	775.7	-877.0	1,189.0
Total liabilities	350.5	355.8	50.3	166.1	922.7	384.4	-877.0	430.1

mEUR	Specialty			Veterinary	Total	Group		Group
Jul-Sep 2025	Pharma	MedTech	Diagnostics	Services	segments	functions	Eliminations	total
Revenue								
Revenue from external customers	46.2	37.1	5.2	15.8	104.3	-	-	104.3
Revenue from internal customers	0.0	0.0	-	0.0	0.1	-	-0.1	-
Total revenue	46.2	37.1	5.2	15.9	104.4	-	-0.1	104.3
Adjusted EBITA	13.6	8.8	0.3	4.6	27.3	-1.8	0.0	25.5
Items affecting comparability	0.0	-1.1	-0.1	0.0	-1.1	-0.5	-	-1.7
EBITA	13.6	7.8	0.2	4.6	26.2	-2.3	0.0	23.9
Amortisation of acquisition-related intangible assets	-3.0	-2.4	-0.2	-0.7	-6.3	-	-	-6.3
Net financial items	-2.1	-6.3	-0.2	0.2	-8.4	4.3	0.0	-4.1
Share of profit of an associate and joint venture	-	-	-	-	-	-	-	-
Profit before tax	8.5	-0.9	-0.3	4.1	11.4	2.0	0.0	13.4
Specification of items affecting comparability								
Acquisition-related costs ¹	-0.0	0.6	0.1	-0.0	0.7	-	-	0.7
Systems update	-	0.2	-	-0.0	0.2	-	-	0.2
Restructuring costs	-0.0	0.1	-	-	0.1	-	-	0.1
IPO and financing related costs	-	-	-	-	-	-0.0	-	-0.0
Other ²	-0.0	0.1	0.0	-	0.1	0.5	-	0.6
Total items affecting comparability	-0.0	1.1	0.1	-0.0	1.1	0.5	-	1.7
Other disclosures								
Investments	1.9	0.7	0.3	0.5	3.3	-	-	3.3
Total assets	514.5	472.7	52.6	163.3	1,203.0	707.3	-787.8	1,122.5
Total liabilities	343.6	359.0	34.3	131.0	867.9	346.7	-787.8	426.8

¹ In MedTech, the majority of the acquisition related costs relate to the acquisitions of AllAccem and Dental Focus, closed in Q2-2025.

² Main items in other are severance pay to the former CEO.

mEUR	Specialty			Veterinary	Total	Group		Group
Jan-Sep 2026	Pharma	MedTech	Diagnostics	Services	segments	functions	Eliminations	total
Revenue								
Revenue from external customers	149.0	130.4	22.2	56.2	357.9	-	-	357.9
Revenue from internal customers	0.0	0.0	0.0	0.2	0.3	-	-0.3	-
Total revenue	149.1	130.5	22.3	56.4	358.2	-	-0.3	357.9
Adjusted EBITA	45.0	33.6	2.2	16.2	97.0	-8.9	0.0	88.1
Items affecting comparability	-0.7	-2.8	-0.5	-2.1	-6.1	1.3	-	-4.8
EBITA	44.3	30.9	1.7	14.1	91.0	-7.6	0.0	83.3
Amortisation of acquisition-related intangible assets	-9.3	-6.7	-0.9	-2.5	-19.3	-	-	-19.3
Net financial items	-12.9	-13.6	-1.2	-9.2	-36.9	18.7	-	-18.2
Share of profit of an associate and joint venture	-	-	-2.5	-	-2.5	-	-	-2.5
Profit before tax	22.2	10.6	-3.0	2.5	32.2	11.1	-0.0	43.3
Specification of items affecting comparability								
Acquisition-related costs	0.1	1.5	0.4	1.2	3.2	-	-	3.2
Systems update	-	-	-	-	-	-	-	-
Restructuring costs	0.3	0.0	0.0	0.1	0.4	-	-	0.4
IPO and financing related costs	-	-	-	-	-	-	-	-
Other ¹	0.3	1.2	0.1	0.9	2.5	-1.3	-	1.2
Total items affecting comparability	0.7	2.8	0.5	2.1	6.1	-1.3	-	4.8
Other disclosures								
Investments	8.3	3.3	2.6	1.3	15.5	0.1	-	15.6
Total assets	539.0	470.5	85.0	195.8	1,290.4	775.7	-877.0	1,189.0
Total liabilities	350.5	355.8	50.3	166.1	922.7	384.4	-877.0	430.1

¹ In Other the segments report paid compensation to the participants in the LTI 2022 programme. The cost is netted to the provision reported by Group functions in Q2-2025.

EURm	Specialty			Veterinary	Total	Group		Group
Jan-Sep 2025	Pharma	MedTech	Diagnostics	Services	segments	functions	Eliminations	total
Revenue								
Revenue from external customers	136.4	115.4	16.8	47.5	316.1	-	-	316.1
Revenue from internal customers	0.0	0.0	-	0.2	0.2	-	-0.2	-
Total revenue	136.5	115.4	16.8	47.7	316.3	-	-0.2	316.1
Adjusted EBITA	40.1	29.7	1.6	13.9	85.4	-6.2	-	79.2
Items affecting comparability	-0.5	-10.2	-0.2	-0.1	-11.1	-2.9	-	-14.0
EBITA	39.6	19.5	1.4	13.8	74.3	-9.1	-	65.2
Amortisation of acquisition-related intangible assets	-9.2	-5.6	-0.7	-2.1	-17.6	-	-	-17.6
Net financial items	-5.5	-15.3	-0.4	-0.5	-21.8	12.6	-4.0	-13.2
Share of profit of an associate and joint venture	-	-	-	-	-	-	-	-
Profit before tax	24.9	-1.4	0.3	11.2	35.0	3.4	-4.0	34.4
Specification of items affecting comparability								
Acquisition-related costs ¹	0.2	2.5	0.2	0.1	3.0	-	-	3.0
Systems update	-	0.8	-	0.0	0.8	-	-	0.8
Restructuring costs	0.3	0.1	-	-	0.4	-	-	0.4
IPO and financing related costs	-	-	-	-	-	0.6	-	0.6
Other ²	0.0	6.8	0.0	-	6.9	2.3	-	9.2
Total items affecting comparability	0.5	10.2	0.2	0.1	11.1	2.9	-	14.0
Other disclosures								
Investments	4.6	1.9	1.0	2.0	9.5	-	-	9.5
Total assets	514.5	472.7	52.6	163.3	1,203.0	707.3	-787.8	1,122.5
Total liabilities	343.6	359.0	34.3	131.0	867.9	346.7	-787.8	426.8

¹ In MedTech the majority of the acquisition related costs relate to the acquisitions of iM3, AllAccem and Dental Focus.

² Main items in other are legal fees related to the US indemnification dispute and provision for compensation to participants in the LTI 2022 programme.

Note 4. Revenue from contracts with customers

EURm	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Jul-Sep 2026					
Geographic region					
Europe	28.4	14.5	5.1	14.5	62.4
North America	18.1	22.1	1.0	3.9	45.2
Rest of the World	3.8	6.7	1.3	0.9	12.7
Revenue from contracts with customers	50.3	43.2	7.4	19.3	120.3
Whereof from products	87%	98%	97%	5%	78%
Whereof from services	13%	2%	3%	95%	22%

EURm	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Jul-Sep 2025					
Geographic region					
Europe	24.7	10.7	3.3	12.5	51.1
North America	18.0	19.8	0.9	2.6	41.4
Rest of the World	3.5	6.6	1.0	0.7	11.8
Revenue from contracts with customers	46.2	37.1	5.2	15.8	104.3
Whereof from products	84%	99%	98%	4%	78%
Whereof from services	16%	1%	2%	96%	22%

EURm	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Jan-Sep 2026					
Geographic region					
Europe	82.5	41.3	14.7	43.0	181.6
North America	55.9	66.9	3.6	10.4	136.8
Rest of the World	10.6	22.2	4.0	2.8	39.5
Revenue from contracts with customers	149.0	130.4	22.2	56.2	357.9
Whereof from products	87%	98%	97%	5%	79%
Whereof from services	13%	2%	3%	95%	21%

EURm	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Jan-Sep 2025					
Geographic region					
Europe	75.6	35.3	10.3	37.5	158.7
North America	50.9	60.3	2.9	7.7	121.7
Rest of the World	10.0	19.8	3.5	2.3	35.6
Revenue from contracts with customers	136.4	115.3	16.8	47.5	316.0
Whereof from products	84%	99%	97%	5%	79%
Whereof from services	16%	1%	3%	95%	21%

The group has significant exposure to the US, 34 per cent (36) and the UK, 12 per cent (13) markets. All other markets individually represent less than 10 per cent of net revenue. Net revenue from external customers in Sweden amounted to EUR 3.9m (4.9) during the third quarter 2026. No individual customer accounts for more than 10 per cent of Group net revenue.

Note 5. Financial instruments

The carrying amount of the Group's financial instruments measured at fair value regards contingent considerations (see below). The carrying amount of other financial assets and liabilities is deemed to be a good approximation of the fair value.

Contingent consideration

In some of the Group's business combinations, part of the purchase price has been in the form of contingent consideration. The contingent considerations depend on the future earnings or sales of the acquired companies.

The contingent considerations will be settled in cash. The contingent considerations are included in the following line items in the statement of financial position for 30 September 2026: other non-current liabilities EUR 24.4 million (28.8) and other current liabilities EUR 7.2 million (13.0). The contingent considerations are measured at fair value by discounting the expected cash flows by a risk adjusted discount rate. The contingent considerations are classified as level 3 in the fair value hierarchy.

The contingent considerations consist of earn-out agreements in business combinations. The earn-out hurdles are typically linked to sales or EBITDA targets for periods ranging 1-5 years after the acquisition date. The earn-outs are discounted and revaluated on an ongoing basis, based on the current performance and forecasted figures for the acquired companies.

There are currently 25 separate obligations, all with their own targets, capped at a maximum amount. The maximum amount payable if all acquisitions would reach their capped amounts is EUR 142.1 million. A 10 per cent increase in the underlying metric (sales or EBITDA) for all acquisitions compared to the current assumptions would lead to an increase of the contingent consideration of EUR 10.4 million.

Contingent consideration, EURm	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Opening balance	46.4	63.7	63.7
Business combinations	8.5	7.9	8.3
Paid out	-29.4	-33.4	-33.6
Change in fair value recognised in P&L	2.9	3.6	5.5
Probability adjustments recognised in the P&L	2.4	1.5	4.1
Exchange differences on translation of foreign operations	0.7	-1.5	-1.5
Closing balance	31.6	41.8	46.4

Note 6. Business combinations

The following acquisitions have been completed during the period January – September 2026:

EURm	Deal type	Acquired %	Based	Segment	Consolidation month	Annual sales
I-Vet s.r.l.	Share	100%	Italy	Diagnostics	Mar	5.6
Favna ApS	Share	70%	Denmark	Veterinary services	Mar	4.3
VetSave Ltd	Share	100%	Ireland	Veterinary services	May	1.7
Verona Pet	Assets		Italy	Diagnostics	Jul	0.4

I-Vet s.r.l.

On 2 March 2026, the Group acquired 100% of the shares in I-Vet. I-Vet is one of the leading providers of companion animal diagnostics in Italy with annual revenues of around EUR 5.6 million.

Favna ApS

On 5 March 2026, the Group acquired 70% of the shares in Favna, that operates veterinary clinics in Denmark, with annual revenues of around EUR 4.3 million.

VetSave Ltd

On 1 May 2026, the Group acquired 100% of the shares in VetSave. VetSave, with annual revenues of around EUR 1.7 million, provides veterinary practices with buying group services and offers a fully transparent solution to the true cost of veterinary medicines, with all rebates and discounts on the day of purchase.

Verona Pet

On 13 July 2026, the Group acquired the assets of the Verona Pet cremation services in Italy. The business has annual revenues of EUR 0.4 million.

Preliminary purchase price allocations per operating segment during the period January – September 2026

Acquired net assets on acquisition date based on preliminary PPA, EURm	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Intangible assets			5.0	6.7	11.7
Property, plant and equipment			2.6	0.4	2.9
Right-of-use assets			-	-	-
Non-current financial assets			0.5	0.1	0.6
Deferred tax assets			-	-	-
Inventories			1.2	0.2	1.4
Trade receivable and other receivables			1.8	6.9	8.7
Cash and cash equivalents			0.1	0.4	0.5
Interest-bearing liabilities			-4.1	-	-4.1
Lease liabilities			-	-	-
Deferred tax liabilities			-1.6	-0.9	-2.4
Trade payables and other operating liabilities			-2.2	-8.2	-10.3
Identified net assets			3.3	5.5	8.8
Non-controlling interest measured at fair value			-	-	-
Goodwill			16.9	10.3	27.2
Total purchase consideration			20.2	15.8	36.0
Purchase consideration comprises:					
Cash			14.8	11.6	26.4
Equity instruments			-	-	-
Contingent consideration and deferred payments			5.3	4.2	9.5
Total purchase consideration			20.2	15.8	36.0

Impact of acquisition on Group's cash flow, EURm	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Cash portion of purchase consideration			14.8	11.6	26.4
Acquired cash			-0.1	-0.4	-0.5
Total			14.7	11.2	25.9
Acquisition-related costs			0.7	0.6	1.2
Net cash outflow			15.3	11.8	27.2

The purchase price allocations of I-Vet, Favna, VetSave and Verona Pet are deemed preliminary. The group does not expect any material deviations from the current numbers.

Note 7. Related-party transactions

There have been no significant changes in the relationships with related parties for the Group or the Parent Company compared to the information provided in the Annual Financial statements for 2025. All related party transactions are at arm's length.

Year to date an amount of EUR 7.7m in licensing income was invoiced to an entity owned by Nick Bova, manager within the Specialty Pharma segment, that owns Pharmacy licenses as part of regulatory restrictions.

Other related party transactions include rent and fee payments to former owners of acquired businesses. The amounts paid in these transactions are insignificant both individually and as a whole.

Note 8. Events after the balance-sheet date

No significant events occurred after the end of the third quarter.

Note 9. Seasonal effects and risks

Seasonal effects

Vimian assesses that its revenues and EBITA to a limited degree are affected by seasonality. The four segments have varying, but limited, seasonality patterns. The strongest seasonality effect can be seen in MedTech, where the first quarter is typically the strongest quarter due to the AOP programme. During 2024 and 2025, Vimian has reduced the AOP to better align shipments with customer demand for the MedTech segment. As a consequence, the revenue will be more evenly spread throughout the year with limited seasonality for MedTech. For all segments, trading volumes are slightly negatively affected by holiday periods.

Risks and uncertainties

Vimian Group's and the parent company's business risks and risk management, as well as the management of financial risks, are described on pages 64-69 in the 2025 Annual Report published at www.vimian.com.

The group has limited exposure to the current geopolitical environment, mainly being the international supply chain for both finished products and raw materials. In case of tariffs or conflicts this could hurt the groups competitive advantage in certain businesses. To mitigate these risks the group is diversifying its supply chains and implementing contingency plans.

Note 10. Restatement of Statement of profit and loss

As from the fourth quarter 2025, Vimian has changed the accounting of elimination of internal management fees. The elimination was previously netting Other operating income and Other external expenses. The change has no other effect on the financial statements. Comparative periods have been restated accordingly.

EURm	Other operating income		Other external expenses	
	Reported	Restated	Reported	Restated
Jan-mar 2025	-0.1	0.7	-23.1	-23.9
Apr-jun 2025	-0.1	1.0	-20.6	-21.7
Jan-jun 2025	-0.2	1.7	-43.8	-45.7
Jul-sep 2025	-0.1	0.6	-18.0	-18.7
Jan-sep 2025	-0.3	2.3	-61.8	-64.4

Note 11. IFRS 18 implementation

IFRS 18 becomes effective for financial years beginning on or after 1 January 2027 and will be applied by Vimian from that date. The standard is to be applied retrospectively to all comparative periods. As IFRS 18 affects only presentation and disclosures and not the measurement of items in the financial statements, the transition is not expected to impact retained earnings.

The primary effects relate to the structure of the income statement, where certain items will be reclassified and new subtotals, such as operating profit, will be introduced. Comparative figures will be restated, and a reconciliation between the previous presentation under IAS 1 and the new presentation under IFRS 18 will be provided. The final analysis of the transition effects and disclosures, as well as the assessment of Management Performance Measures (MPM), is still ongoing.

ALTERNATIVE PERFORMANCE MEASURES

Alternative Performance Measures (APMs) are financial measures of historical or future financial performance, financial position or cash flows that are not defined in applicable accounting regulations (IFRS). APMs are used by Vimian when it is relevant to monitor and describe Vimian's financial situation and to provide additional useful information to users of financial statements. These measures are not directly comparable to similar key ratios presented by other companies.

Key Ratios	Definition	Reason for usage
Organic Revenue Growth	Change in Revenue in relation to the comparative period adjusted for acquisition and divestment effects and any currency impacts. Acquired businesses are included in Organic growth when they have been part of the Group for 12 months and divested businesses are excluded from Organic growth from the date of divestment in the current and comparative period. The Currency impact is calculated by translating the accounts for year N-1 of subsidiaries having a functional currency different than the currency of the issuer with N exchange rate.	Organic growth is used by investors, analysts and the company's management to monitor the underlying development of revenue between different periods at constant currency and excluding the impact of any acquisitions and/or divestments.
EBIT	Operating profit as reported in the Income statement, i.e. profit for the period excluding finance income, finance costs, share of profit of an associate and income tax expense.	The measure shows the profitability from the operations of the parent company and its subsidiaries.
EBITA	Operating profit excluding amortisation of intangible assets that were originally recognised in connection with business combinations.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation of intangible assets as well as independent of taxes and the Company's financing structure.
EBITDA	Operating profit excluding amortisation, depreciation and impairment of intangible and tangible assets.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure.
Adjusted EBITA	EBITA adjusted for items affecting comparability.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation of intangible assets as well as independent of taxes and the Company's financing structure. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Adjusted EBITA margin	Adjusted EBITA in relation to Revenue.	The measure reflects the business's operating profitability before amortisation of intangible assets. The measure is an important component, together with revenue growth, to follow the Company's value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Adjusted EBITDA	EBITDA adjusted for items affecting comparability.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Adjusted EBITDA margin	Adjusted EBITDA in relation to Revenue.	The measure reflects the business's operating profitability before amortisation and depreciation of intangible and tangible fixed assets. The measure is an important component, together with revenue growth, to follow the Company's value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Items affecting comparability	Income and expense items that are considered to be important to specify to users of the financial information since they affect comparability.	A separate disclosure of items affecting comparability is relevant to provide to users of the financial information to give further understanding of the financial performance when comparing of financial performance between periods. Generally accepted NRI's include acquisition and integration related costs, litigation related costs if material, significant restructuring costs (e.g., the consolidation of production footprint in Diagnostics going from four to two production sites), costs related to projects such as the initial public offering.

Key Ratios	Definition	Reason for usage
Amortisation PPA related	Amortisation of intangible assets that were originally recognised in connection with business combinations.	Specification of amortisation in different categories since management differentiates amortisation when calculating EBITA.
Net debt	Cash and cash equivalents less liabilities to credit institutions, lease liabilities, other non-current liabilities and specific items included in other current liabilities (contingent considerations, deferred payments, vendor notes and shareholder loans related to business combinations).	Net debt is a measure used to follow the development of debt and the size of the refinancing need. Since cash and cash equivalents can be used to pay off debt at short notice, net debt is used instead of gross debt as a measure of the total loan financing.
Net debt / Adjusted EBITDA (pro-forma)	Net debt in relation to a 12-month period of Adjusted EBITDA (pro-forma).	The measure is a debt ratio that shows how many years it would take to pay off the Company's debt, provided that its net debt and Adjusted EBITDA are constant and without taking into account the cash flows regarding interest, taxes and investments. Net Debt / Adjusted EBITDA is referred to in the report as leverage.
Net Working Capital	Inventory, Trade receivables, Current tax receivables, Other current receivables, Prepaid expenses and Accrued income, less Trade payables, Current tax liabilities, Accrued expenses and deferred income, Provisions and Other current liabilities (excluding contingent considerations, deferred payments, vendor notes and shareholder loans related to business combinations)	Working capital is a measure of the company's short-term financial status
Capex	Total cash flow from investments in tangible and intangible assets during the period. This includes costs for internally developed assets.	Capex is a measure of the company's historical investments and is used as input in calculating Free cash flow and Cash conversion.
Proforma revenue	Reported revenue for the last twelve months plus revenue for all acquisitions closed during the last twelve months, as if they had been consolidated the full period.	The measure reflects a fair view of the business's revenue for a full year period.
Adjusted EBITA, Proforma	Reported adjusted EBITA for the last twelve months adding the adjusted EBITA for all acquisitions closed during the last twelve months, as if they had been consolidated the full period.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period.
Adjusted EBITDA, Proforma	Reported adjusted EBITDA for the last twelve months adding the adjusted EBITDA for all acquisitions closed during the last twelve months, as if they had been consolidated the full period.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period.
Adjusted EBITA and EBITDA margin, Proforma	Adjusted proforma EBITA and EBITDA in relation to proforma revenue.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is an important component, together with revenue growth, to follow the Company's value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period.
Acquisition related expenses	Expenses related to legal and financial due diligence as well as in some cases stay on bonuses to key personnel. If specific initial integration costs are required, and agreed upon during the acquisition process, this can be considered as acquisition related expenses.	
Restructuring costs	Costs relating to significant change of business model or operational structure. Possibly linked to integration between legacy and acquired businesses. The most significant restructuring project to date is the consolidation of production footprint in Diagnostics going from four to two production sites.	

Alternative performance measures not defined in accordance with IFRS for the group - Based on proforma figures

EURm (unless otherwise stated)	1 Jul-30 Sep		1 Jan-30 Sep		1 Jan-31 Dec
	2026	2025	2026	2025	2025
Revenue growth (%)	15%	19%	13%	17%	13%
Organic revenue growth (%)	11%	9%	10%	6%	6%
Revenue	120.3	104.3	357.9	316.1	425.0
EBITDA	31.8	27.4	96.0	75.4	104.8
EBITDA margin (%)	26.5%	26.3%	26.8%	23.9%	24.7%
Items affecting comparability	-2.1	-1.7	-4.8	-14.0	-14.7
Adjusted EBITDA	33.9	29.1	100.8	89.4	119.5
Adjusted EBITDA margin (%)	28.2%	27.9%	28.2%	28.3%	28.1%
EBITA	27.1	23.9	83.3	65.2	90.7
EBITA margin (%)	22.5%	22.9%	23.3%	20.6%	21.3%
Adjusted EBITA	29.2	25.5	88.1	79.2	105.3
Adjusted EBITA margin (%)	24.3%	24.5%	24.6%	25.1%	24.8%
Operating profit	20.5	17.5	64.0	47.6	66.8
Operating margin (%)	17.0%	16.8%	17.9%	15.1%	15.7%
Capital expenditure	-4.1	-3.1	-15.6	-9.3	-15.1
Cash flow from operating activities	22.6	10.8	49.4	50.1	105.7

EURm (unless otherwise stated)	1 Oct - 30 Sep
	LTM (2025/2026)
Proforma revenue	472.5
Adjusted EBITDA, Proforma	132.3
Adjusted EBITDA margin, Proforma	28.0%
Net debt	262.4
Net debt / Adjusted EBITDA, Proforma (x)	2.0x

Reconciliation of alternative performance measures not defined in accordance with IFRS for the group

Certain statements and analyses presented include alternative performance measures (APMs) that are not defined by IFRS. The Company believes that this information, together with comparable defined IFRS metrics, are useful to investors as they provide a basis for measuring operating profit and ability to repay debt and invest in operations. Corporate management uses these financial measurements, along with the most directly comparable financial metrics under IFRS, to evaluate operational results and value added. The APMs should not be assessed in isolation from, or as a substitute for, financial information presented in the financial statements in accordance with IFRS. The APMs reported are not necessarily comparable to similar metrics presented by other companies. The reconciliations are presented in the tables below:

EURm (unless otherwise stated)	1 Jul-30 Sep		1 Jan-30 Sep		1 Jan-31 Dec
	2026	2025	2026	2025	2025
EBITA/EBITDA and Adjusted EBITA/EBITDA					
Revenue	120.3	104.3	357.9	316.1	425.0
EBIT	20.5	17.5	64.0	47.6	66.8
Amortisation of acquisition related intangibles	6.6	6.3	19.3	17.6	23.8
EBITA	27.1	23.9	83.3	65.2	90.7
Other depreciation	4.7	3.5	12.7	10.2	14.1
EBITDA	31.8	27.4	96.0	75.4	104.8
Items affecting comparability	2.1	1.7	4.8	14.0	14.7
Adjusted EBITA	29.2	25.5	88.1	79.2	105.3
Adjusted EBITDA	33.9	29.1	100.8	89.4	119.5
EBITA margin (%)	22.5%	22.9%	23.3%	20.6%	21.3%
EBITDA margin (%)	26.5%	26.3%	26.8%	23.9%	24.7%
Adjusted EBITA margin (%)	24.3%	24.5%	24.6%	25.1%	24.8%
Adjusted EBITDA margin (%)	28.2%	27.9%	28.2%	28.3%	28.1%

EURm (unless otherwise stated)	30 Sep		31 Dec
	2026	2025	2025
Net debt			
Liabilities to credit institutions (long term)	263.1	254.0	223.3
Lease liabilities (long term)	12.1	11.0	10.3
Other non-current liabilities	28.2	28.8	20.9
Liabilities to credit institutions (short term)	0.0	-0.2	0.0
Lease liabilities (short term)	5.0	5.0	5.1
Other items ¹	10.1	30.7	42.3
Cash & Cash Equivalents	-55.6	-51.3	-55.0
Other receivables	-0.6	-24.6	-1.5
Net debt	262.4	253.5	245.4

EURm (unless otherwise stated)	30 Sep		31 Dec
	2026	2025	2025
Net working capital			
Inventory	98.3	80.9	80.1
Trade receivables	67.5	57.6	57.3
Current tax receivables	4.5	2.2	1.2
Other current receivables	6.9	8.5	6.7
Prepaid expenses and accrued income	14.6	12.2	13.2
Trade payables	-28.1	-18.5	-20.1
Current tax liabilities	-10.3	-10.6	-10.3
Other current liabilities ²	-11.3	-8.3	-11.5
Provisions	-1.6	-0.3	-0.8
Accrued expenses and deferred income	-24.1	-21.4	-19.2
Net working capital	116.4	102.2	96.6

¹ Shareholder loans, deferred payments, vendor notes and contingent considerations included in other current liabilities

² Other current liabilities as reported in the statement of financial position less shareholder loans, deferred payments, vendor notes and contingent considerations related to business combinations

EURm (unless otherwise stated)	1 Oct - 30 Sep	1 Jan-31 Dec
	LTM (2025/2026)	2025
Proforma revenue		
Reported revenue	466.9	425.0
Proforma period, revenue	5.6	5.3
Proforma revenue	472.5	430.4
Adjusted EBITA, Proforma		
Reported Adjusted EBITA (12 months)	114.3	105.3
Proforma period Adjusted EBITA	1.3	3.6
Adjusted EBITA, Proforma	115.6	108.9
Adjusted EBITA margin, Proforma		
Proforma Revenue	472.5	430.4
Adjusted EBITA, Proforma	115.6	108.9
Adjusted EBITA margin, Proforma	24.5%	25.3%
Adjusted EBITDA, Proforma		
Reported Adjusted EBITDA (12 months)	130.9	119.5
Proforma period Adjusted EBITDA	1.5	3.7
Adjusted EBITDA, Proforma	132.3	123.1
Adjusted EBITDA margin, Proforma		
Proforma Revenue	472.5	430.4
Adjusted EBITDA, Proforma	132.3	123.1
Adjusted EBITDA margin, Proforma	28.0%	28.6%
Net debt/Adjusted EBITDA, Proforma		
Net debt	262.4	245.4
Adjusted EBITDA, Proforma	132.3	123.1
Net debt/Adjusted EBITDA, Proforma (x)	2.0x	2.0x



Financial calendar

24 November 2026

Capital Markets Day

11 February 2027

Year-end report 2026

28 April 2027

Interim Report Q1 2027

Annual General Meeting

16 July 2027

Interim Report Q2 2027

21 October 2027

Interim Report Q3 2027

For further information, please contact

Carl-Johan Zetterberg Boudrie
CFO

carl-johan.zetterberg@vimian.com

+46 703 35 84 49

Maria Dahllöf Tullberg

Head of IR, Communications & ESG

maria.tullberg@vimian.com

+46 736 26 88 86

Vimian Group AB (publ) Reg. no. 559234-8923
Riddargatan 19
114 57 Stockholm
Sweden
www.vimian.com